HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gout With Hyperuricemia in Adults
Conditions
Gout With Hyperuricemia in Adults
Trial Timeline
Dec 14, 2023 → Sep 4, 2025
NCT ID
NCT06139393About HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Gout With Hyperuricemia in Adults. The current trial status is completed. This product is registered under clinical trial identifier NCT06139393. Target conditions include Gout With Hyperuricemia in Adults.
What happened to similar drugs?
7 of 20 similar drugs in Gout With Hyperuricemia in Adults were approved
Approved (7) Terminated (3) Active (11)
🔄SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06414837 | Phase 3 | Recruiting |
| NCT06139393 | Phase 3 | Completed |
| NCT05347498 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Gout With Hyperuricemia in Adults